CRISPR Becomes Clearer. Issue 5 (September 2017)

• Record Type: Journal Article
• Authors: Torrance, Andrew W.
• Is Part Of: Hastings Center report. Volume 47:Issue 5(2017)
• Page Start: 5
• Page End: 6
• Publication Date: 2017-09
• Subjects: Medical ethics -- Periodicals; Bioethics -- Periodicals; 174.205
• DOI: 10.1002/hast.762
• Languages: English
• ISSNs: 0093-0334

Abstract

Abstract: In this pivotal year for gene editing, the breakthrough molecular system CRISPR–Cas9 has advanced on three fronts. In under seven months, an influential scientific body—the National Academies of Sciences, Engineering, and Medicine the National Academies of Sciences, Engineering, and Medicine—cracked open the door to human germline gene editing, ownership of patents covering CRISPR–Cas9 came into much sharper focus as a result of a dispute between two parties, and experiments showing proof of concept of the most controversial of uses—altering germlines of humans—were revealed as having been successfully performed by a mainstream laboratory. Given the vast spoils that await the patent owners, final results of all patent disputes over CRISPR–Cas9 patents may stretch on for years. Meanwhile, bioethical considerations of CRISPR–Cas9 have also been contentious as the United States and other countries grapple with how best to regulate gene editing.